Stockscreener 앱 받기
18.50
6.63%
1.15
시간 외 거래:
18.69
0.19
+1.03%
전일 마감가:
$17.35
열려 있는:
$17.86
하루 거래량:
3.90M
Relative Volume:
1.70
시가총액:
$4.38B
수익:
$382.81M
순이익/손실:
$68.13M
주가수익비율:
66.07
EPS:
0.28
순현금흐름:
$78.82M
1주 성능:
+4.64%
1개월 성능:
+16.79%
6개월 성능:
+4.82%
1년 성능:
+197.43%
1일 변동 폭
$17.80
$18.56
1주일 범위
$15.88
$18.56
52주 변동 폭
$5.88
$23.64
Adma Biologics Inc Stock (ADMA) Company Profile
명칭
Adma Biologics Inc
전화
(201) 478-5552
주소
C/O ADMA BIOLOGICS, INC., RAMSEY
ADMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
18.50 | 4.38B | 382.81M | 68.13M | 78.82M | 0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-19 | 재개 | Raymond James | Strong Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 개시 | Jefferies | Buy |
| 2019-04-15 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-07 | 재개 | H.C. Wainwright | Buy |
| 2017-12-11 | 재확인 | Maxim Group | Buy |
| 2017-11-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2016-08-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-07-25 | 재확인 | Maxim Group | Buy |
| 2015-05-13 | 재확인 | Maxim Group | Buy |
| 2014-12-08 | 개시 | Oppenheimer | Outperform |
| 2014-12-01 | 재확인 | Maxim Group | Buy |
모두보기
Adma Biologics Inc 주식(ADMA)의 최신 뉴스
Adma Biologics (ADMA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
What's Driving the Market Sentiment Around ADMA Biologics? - Benzinga
Commit To Buy ADMA Biologics At $10, Earn 14% Using Options - Nasdaq
Bank of New York Mellon Corp Has $26.09 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Mutual of America Capital Management LLC Has $614,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook - MSN
Lost Money on ADMA Biologics, Inc. (ADMA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Lisanti Capital Growth LLC Sells 59,565 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Mizuho lifts ADMA Biologics price target to $32, maintains Outperform - Investing.com
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85% - MSN
ADMA Biologics Stock Climbs Amid Strong Earnings - TipRanks
ADMA Biologics (NASDAQ:ADMA) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects - TipRanks
ADMA Biologics Earnings Call Highlights Strong Growth - TipRanks
ADMA Biologics Inc earnings beat by $0.31, revenue topped estimates - Investing.com Australia
BREAKING: Block & Leviton Investigating ADMA Biologics, - GlobeNewswire
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed - EIN News
ADMA Biologics slips as 10-K delay overshadows earnings beat - MSN
ADMA Biologics stock slips on 10-K delay (ADMA:NASDAQ) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2024 Earnings Call Transcript - Insider Monkey
ADMA Biologics Reports Strong 2024 Financial Performance - MSN
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Earnings call transcript: ADMA Biologics Q4 2024 beats EPS forecast - Investing.com India
ADMA Biologics Delays 10-K Filing Amid Auditor Change - TipRanks
Earnings call transcript: ADMA Biologics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
ADMA Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ADMA BIOLOGICS Earnings Results: $ADMA Reports Quarterly Earnings - Nasdaq
Adma Biologics sees FY26 revenue at least $605M - TipRanks
Adma Biologics: Q4 Earnings Snapshot - CTPost
ADMA Biologics Swings to Q4 Profit, Revenue Increases; Shares Rise After Hours -March 03, 2025 at 04:47 pm EST - Marketscreener.com
ADMA Biologics stock jumps over 4% on strong Q4 results, raised guidance - Investing.com
Adma Biologics: Q4 Earnings Snapshot -March 03, 2025 at 04:40 pm EST - Marketscreener.com
ADMA Biologics Reports Strong Financial Performance in 2024 - TradingView
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
ADMA Biologics Reports 65% Revenue Growth and Significant Increase in Net Income for FY 2024 - Nasdaq
Earnings Flash (ADMA) Adma Biologics Reports Q4 Revenue $117.5M, vs. FactSet Est of $112.8M - Marketscreener.com
Adma Biologics options imply 11.5% move in share price post-earnings - TipRanks
Earnings Scheduled For March 3, 2025 - Benzinga
New York State Common Retirement Fund Sells 11,550 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Shareholder Rights Advocates at Levi & Korsinsky Investigate ADMA Biologics, Inc. (ADMA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Okta, Gitlab, ADMA Biologics set to report earnings Friday By Investing.com - Investing.com South Africa
Okta, Gitlab, ADMA Biologics set to report earnings Friday - Investing.com
ADMA Biologics Inc (ADMA) Q4 2024: Everything You Need To Know A - GuruFocus.com
ADMA Biologics Inc (ADMA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference - GlobeNewswire
Adma Biologics Inc (ADMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.70%
자본화:
|
볼륨(24시간):